Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Authors :: Christian Confavreux
J. A. Cohen
Vesna V. Brinar
K. Selmaj
Michael Panzara
Eva Havrdova
Howard L. Weiner
David Margolin
Gavin Giovannoni
Edward Fox
Alasdair Coles
Jan Lycke
D. A. S. Compston
Douglas L. Arnold
Stephen Lake
H.-P. Hartung
Miroslav Stojanovic
Source :: Journal of the Neurological Sciences. 333:e374-e375
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Multiple sclerosis
medicine.disease
Therapy naive
Neurology
Internal medicine
medicine
Alemtuzumab
Neurology (clinical)
business
Adverse effect
medicine.drug

Full Text Access

Tools